Suppr超能文献

体外对人肾脏及肾癌多药耐药性的规避

Circumvention of multi-drug resistance in human kidney and kidney carcinoma in vitro.

作者信息

Volm M, Pommerenke E W, Efferth T, Löhrke H, Mattern J

机构信息

German Cancer Research Center, Department of Experimental Pathology, Heidelberg.

出版信息

Cancer. 1991 May 15;67(10):2484-9. doi: 10.1002/1097-0142(19910515)67:10<2484::aid-cncr2820671016>3.0.co;2-i.

Abstract

This report investigated whether the calmodulin inhibitor, trifluoperazine, can circumvent multi-drug resistance both in primary tissue cultures of human kidney and kidney carcinoma. For detection of inherent multi-drug resistance, the expression of P-glycoprotein was determined by immunofluorescence and immunocytochemistry using the monoclonal antibody C219. For detection of doxorubicin resistance and reversal of this resistance by trifluoperazine, the incorporation of nucleic acid precursor was measured after addition of doxorubicin and trifluoperazine, respectively. Both P-glycoprotein expressing resistant normal and malignant kidney tissue cultures could be modified by trifluoperazine. However, sensitive normal kidney and kidney carcinoma cultures were little affected by trifluoperazine. Thus, circumvention of primary resistance to doxorubicin is not limited to tumor cells. This might have important implications for the use of resistance modifiers in the clinical setting.

摘要

本报告研究了钙调蛋白抑制剂三氟拉嗪是否能够克服人肾原代组织培养物和肾癌中的多药耐药性。为检测内在多药耐药性,使用单克隆抗体C219通过免疫荧光和免疫细胞化学法测定P-糖蛋白的表达。为检测阿霉素耐药性以及三氟拉嗪对这种耐药性的逆转作用,分别在加入阿霉素和三氟拉嗪后测量核酸前体的掺入情况。表达P-糖蛋白的耐药性正常和恶性肾组织培养物均可被三氟拉嗪修饰。然而,敏感的正常肾和肾癌培养物受三氟拉嗪的影响很小。因此,对阿霉素原发耐药性的克服并不局限于肿瘤细胞。这可能对临床上耐药性调节剂的使用具有重要意义。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验